TGT Stock UPDATES Target Corp (TGT) 58.54 08/08/2014 22:47:0

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Target Corp (TGT) 58.54 $TGT

Final Glance: Big-box Retail companies
AP - Fri Aug 08, 5:06PM CDT
NEW YORK (AP) — Shares of some top big-box retail companies were up at the close of trading:

Recalls this week: televisions, bar stools
By The Associated Press - AP - Fri Aug 08, 2:07PM CDT
Nearly 250,000 televisions with a potentially faulty stand assembly are among this week's recalled products. Others include potentially defective dive watches and bar stools.

Target (TGT) Crosses Pivot Point Resistance at $58.16
Comtex SmarTrend(R) - Fri Aug 08, 12:59PM CDT
Shares of Target (NYSE:TGT) opened today above their pivot of $57.71 and have already reached the first level of resistance at $58.16. Analysts will be watching for a cross of the next upside pivot targets of $58.80 and $59.89.

Discount Retailers: Investing Essentials
Adam Levine-Weinberg, The Motley Fool - Motley Fool - Fri Aug 08, 11:05AM CDT
In the past several decades, discount retailers have become the go-to shopping destinations for most Americans, displacing department stores and even (to some extent) grocery stores. By and large, people are willing to sacrifice a little bit in...

21st Century Fox Jumps on Earnings Beat: Tech Winners & Losers
at The Street - Thu Aug 07, 11:54AM CDT
Despite abandoning its proposed deal with Time Warner, 21st Century Fox beat earnings expectations, while Amazon.com shares fell in response to a threat from Google and Barnes & Noble.

'Fast Money' Recap: Seeking Security in Glittering Gold
at The Street - Thu Aug 07, 4:00AM CDT
The trading panel discussed falling equities, Twenty-First Century Fox' earnings and whether Pandora can take market share in sports radio from Sirius.

Business Highlights
By The Associated Press - AP - Wed Aug 06, 5:14PM CDT
___

Target Slips on Q2 Preliminary Guidance Cut & Higher Expense - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 4:30PM CDT
Shares of Target (TGT) dipped 4.4% yesterday as the retail giant made few preliminary announcements on its second-quarter 2014 results.

History Repeats in Walgreens Deal for Alliance Boots
at The Street - Wed Aug 06, 10:19AM CDT
Investors hated Walgreens decision to buy Alliance Boots in 2012.

Target publicly endorses same-sex marriage
Star Tribune - Wed Aug 06, 10:18AM CDT
MINNEAPOLIS (AP) — Target Corp. is adding its name to a legal defense of gay marriage, joining other large companies that are taking a stand, just four years after the retailer came under criticism for supporting a strident opponent of same-sex unions.

Stock Market News for August 06, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 9:10AM CDT
Benchmarks settled in the red zone following reports that Russia has increased forces along its border with Ukraine

Target to Sponsor 2014 ASP Maui Women's Pro Surfing Competition
Business Wire - Wed Aug 06, 9:00AM CDT
Target Corp. (NYSE: TGT), along with the Association of Surfing Professionals (ASP), today announced that the retailer will be the title sponsor of this season's Maui Women's Pro, November 22 through December 6, 2014 in Honolua Bay, Maui.

Downgrade Alert for Target (TGT)
Comtex SmarTrend(R) - Wed Aug 06, 8:02AM CDT
Target (NYSE:TGT) was downgraded from Buy to Neutral at Goldman Sachs today. The stock closed yesterday at $58.03 on volume of 14.9 million shares, above average daily volume of 4.5 million. Over the past year, Target has traded in a range of $54.66 to $72.07 and closed yesterday at $58.03, 6% above that low. Over the past week, the 200-day moving average (MA) has remained constant while the 50-day MA has advanced 0.3%.

How Will Target (TGT) Stock Be Affected By This Ratings Downgrade?
at The Street - Wed Aug 06, 8:00AM CDT
Target (TGT) was downgraded to 'neutral' from 'buy' at Goldman Sachs (GS).

Why Target���s New Comments Should Worry Investors
at The Street - Wed Aug 06, 6:05AM CDT
Target has just issued a major earnings warning. Brian Sozzi shares why this should really frighten investors.


Asia stocks fall on Russia-Ukraine concerns
BY KAY JOHNSON - AP - Tue Aug 05, 11:26PM CDT
MUMBAI, India (AP) — Worries over Russian troops amassing near the Ukraine border sent most Asian stock markets lower Wednesday.
1 Comment

Jim Cramer's 'Mad Money' Recap: It's Russia's Fault
at The Street - Tue Aug 05, 7:14PM CDT
If Russia wasn't front and center, the markets would be higher.

Report: Russian hackers steal 1.2B passwords
AP - Tue Aug 05, 6:31PM CDT
NEW YORK (AP) — Russian hackers have stolen 1.2 billion user names and passwords in a series of Internet heists affecting 420,000 websites, according to a report published Tuesday.

Target discounts Q2 outlook
at Investor's Business Daily - Tue Aug 05, 5:51PM CDT
Shares of the big-box retailer dropped 4.4% to 58.03 after Target (TGT) slashed its earnings outlook to 78 cents a share vs. prior guidance for 85 cents to $1, plus estimated costs of $148 mil in gross expenses related to its Dec. '13 data breach....




Scroll down for more posts ▼

Top 10 Most Recent News Articles

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 31

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 655

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 406

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 83

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 18

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 55

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 45

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

VivoPower Innovates with XRP-Focused Treasury Strategy

Updated Category News Views 359

VivoPower's Transformational XRP Strategy VivoPower International PLC (NASDAQ: VVPR) has recently embarked on a groundbreaking journey by announcing a new strategy centered on the digital asset XRP. The company is positioning itself as the first publicly traded entity to implement an XRP-focused digital asset treasury. This innovative approach is not only exciting for...

Continue Reading
Recognizing Excellence in Product Stewardship for 2024

Updated Category News Views 114

Celebrating Product Stewardship Excellence The Product Stewardship Society has announced a significant honor for 2024—Lynn L. Bergeson has been named the recipient of the prestigious Allan K. Fleeger Distinguished Service Award. This esteemed award has been established to acknowledge the remarkable contributions of individual product stewards who have played crucial...

Continue Reading
Gold Hits New Heights Amid Tensions and Election Uncertainty

Updated Category News Views 163

Gold Prices Surge to Record Heights In recent trading, gold prices have reached unprecedented levels, reflecting a significant rise driven by various factors, including political uncertainties and ongoing international conflicts. As anticipation surrounding a highly competitive U.S. presidential election grows, along with persistent tensions in regions such as the Middle...

Continue Reading
Paul Jebely Joins Sterlington as Aviation Law Vice Chair

Updated Category News Views 257

Paul Jebely Joins Sterlington as New Partner Sterlington PLLC is excited to announce that Paul Jebely has joined the firm as their new Partner and Vice Chair of International, marking a crucial advancement in their aviation law practice. Jebely is not just any attorney; he is a globally recognized authority in private aviation law, especially known for his work with...

Continue Reading
William James Wartinbee III Executes Significant Sell Strategy

Updated Category News Views 62

William James Wartinbee III Implements Key Sell Strategy In a noteworthy insider sale, William James Wartinbee III, the Executive Vice President at Gartner (IT), has sold 210 shares of the company. This transaction was documented in a Form 4 filing with the U.S. Securities and Exchange Commission, and the sale was valued at about $103,275. Examining Gartner's Current...

Continue Reading